Astellas Venture Management LLC — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Mogrify is a biotechnology company developing in vivo cellular reprogramming therapies, using its proprietary MOGRIFY and epiMOGRIFY platforms that apply transcriptomic and epigenetic data to identify transcription factor combinations for converting one cell type into another.
BiotechDeep TechHealthtech
Julian Gough(Co-founder)inOwen Rackham(Co-founder)inJose Polo(Co-founder)inDarrin M. Disley(CEO)in
BoardJane Osbourn(Chair)
Co-investorsAhren Innovation CapitalParkwalk Advisors
Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.
AI & Machine LearningBiotechBoston, US
George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)inKazumi Shiosaki(President & CEO)in
BoardMichal Silverberg(Director)
Co-investorsOUP (Osage University Partners)Sofinnova PartnersMPM BioImpact
mRNA/LNP based in vivo cell rejuvenation
Mountain View, US
Vittorio Sebastiano(Director)Marco Quarta(Director)Anja Krammer(Executive Officer, Director)Sergio Andres Ruiz-Chinchilla(Executive Officer)Ric Peterson(Executive Officer)
BoardDavid Gobel(Director)
Co-investorsFormic VenturesGaingelsMethuselah FundsKhosla VenturesShanda Group
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.












__Twitter.png)
